Core Insights - Quantum BioPharma Ltd. has reported significant advancements in its clinical trials and financial performance for the year ended December 31, 2024, including the completion of the unbuzzd™ clinical trial and progress in the Lucid-21-302 Phase 1 trial for multiple sclerosis [1][12][14] Financial Performance - The company reported cash and cash equivalents of $12.1 million USD as of December 31, 2024, an increase from $11.1 million USD in 2023 [3] - Operating expenses were reduced to $16.1 million USD in 2024, down from $23.8 million USD in 2023, marking an improvement of over 32% [3] - Net cash used in operations decreased to $6.9 million USD in 2024 from $10.8 million USD in 2023, reflecting a 36% improvement [4] - The net loss for the year was $14.9 million USD, an 18% improvement compared to a net loss of $18.2 million USD in 2023 [6] Clinical Developments - The unbuzzd™ clinical trial demonstrated that the product significantly accelerated the reduction of Blood Alcohol Concentration (BAC) by over 40% faster within 30 minutes compared to control subjects, while also alleviating symptoms of intoxication and hangover [9][13] - The company has initiated the development of rekvry™, a treatment for alcohol misuse, aimed at addressing unmet healthcare needs [8] - The Lucid-21-302 drug for multiple sclerosis has completed a Phase 1 trial, showing safety and tolerability, and is preparing for a Phase 2 trial [14][16] Strategic Initiatives - Celly Nutrition Corp., the licensee for unbuzzd™, is exploring an initial public offering (IPO) and has engaged a New York investment bank to raise up to $10 million USD [9][15] - The company has diversified its treasury by purchasing $3.5 million worth of Bitcoin and other cryptocurrencies, reflecting a strategic approach to enhance liquidity [16][17] - Quantum BioPharma is focused on expanding the distribution of unbuzzd™ through partnerships and e-commerce initiatives [18]

Core Viewpoint - Quantum BioPharma Ltd. has appointed Terry Lynch to its board of directors, replacing Dr. Sanjiv Chopra, who will continue as an advisor to the company [1][3]. Group 1: Appointment Details - Terry Lynch is recognized for founding Save Canadian Mining and has a successful history as an executive in public micro-cap companies [2]. - Lynch is currently the CEO of Power Metallic Mines Inc., which recently secured $50 million in financing [2]. - He is also a co-founder of Cardiol Therapeutics, focusing on cannabidiol for cardiovascular disease treatment [2]. Group 2: Contributions to the Company - CEO Zeeshan Saeed highlighted three key contributions Lynch brings: extensive fundraising experience, biotech investment knowledge, and expertise in stock market manipulation [3]. - Lynch expressed excitement about joining Quantum BioPharma, emphasizing the company's potential and commitment to fairness in capital markets [3]. Group 3: Stock Options - The company granted Lynch 50,000 stock options to acquire Class B Shares at an exercise price of C$9.90, expiring on March 26, 2027 [3]. Group 4: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [4]. - The company is advancing its lead compound, Lucid-MS, aimed at preventing myelin degradation associated with multiple sclerosis [4]. - Quantum BioPharma retains a 25.71% ownership in Celly Nutrition, which includes a royalty agreement on sales from its product unbuzzd™ [4].

Core Viewpoint - Quantum BioPharma Ltd. announced the launch of new unbuzzd™ "On-the-Go Powder Stick Packs" in 8-pack display boxes, aimed at enhancing retail availability and sales in the U.S. market for hangover cure products, which is valued at approximately $2.1 billion [1][5][10]. Product Details - unbuzzd™ is now available in various formats including 3-packs, 8-packs, and 18-packs, with the 8-pack designed for easy portability and compliance with TSA regulations [2][4]. - The compact design and eye-catching packaging of the 8-pack display box make it appealing for retailers to sell at checkout locations [4][5]. Market Strategy - The introduction of the 8-pack display box is expected to meet diverse consumer needs and accelerate retail availability, thereby boosting sales and profits for retailers [5]. - The product aims to leverage immediate availability in convenience, liquor, and drug stores as a key growth driver [5][10]. Clinical Validation - A recent clinical trial demonstrated the effectiveness of unbuzzd™ in reducing blood alcohol concentration, restoring mental clarity, and alleviating hangover symptoms [6][10]. - The product is scientifically backed by a double-blind, randomized, placebo-controlled clinical trial [10]. Financial Arrangement - Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition and has established a royalty agreement of 7% on unbuzzd™ sales until total payments reach $250 million, after which the royalty rate will decrease to 3% [6][12]. Corporate Update - Quantum BioPharma has engaged TD Media LLC to enhance market awareness for a fee of $55,000 over a 45-day period starting March 26, 2025 [8].

Core Viewpoint - Quantum BioPharma Ltd. has strategically increased its cryptocurrency holdings by purchasing an additional USD $1,500,000 worth of Bitcoin and other cryptocurrencies, bringing the total to USD $3,500,000, reflecting the company's belief in the potential of these assets for shareholder returns and as a hedge against the dollar [1][2]. Group 1: Cryptocurrency Investment - The company has received approval from its Board of Directors for the additional cryptocurrency purchase, indicating a strong commitment to this investment strategy [1]. - Quantum BioPharma plans to continue allowing future financings and transactions to be conducted in cryptocurrency, enhancing its financing prospects [2]. - All cryptocurrency holdings are managed by a fully compliant custodian, ensuring adherence to financial and audit regulations [3]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, aimed at preventing myelin degradation [4]. - The company retains a 25.71% ownership stake in Celly Nutrition Corp., which is involved in the UNBUZZD™ product line, and is entitled to royalty payments from sales until a total of $250 million is reached [4]. - Quantum BioPharma maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by real estate [4].

Core Viewpoint - Quantum BioPharma Ltd. has successfully completed a Phase 1 trial for its compound Lucid-MS, which showed no safety concerns and was well-tolerated in healthy participants, paving the way for future clinical development [1][3][4] Group 1: Trial Results - The final safety review committee found that Lucid-MS was well-tolerated with no serious adverse events reported during the trial [1] - The trial was a Phase 1, randomized, double-blind, placebo-controlled study evaluating the safety and pharmacokinetics of Lucid-21-302 in healthy adult participants [1] Group 2: Product Information - Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound aimed at treating multiple sclerosis (MS) by stabilizing the myelin sheath surrounding nerve fibers [2] - The compound is a patented New Chemical Entity (NCE) that has demonstrated the ability to prevent and reverse myelin degradation in preclinical models [5] Group 3: Future Development Plans - The completion of the Phase 1 trial allows the company to move forward with plans for a Phase 2 trial in MS patients [3][4] - The company aims to achieve drug approval and commercialization of Lucid-MS, focusing on arresting demyelination in MS [4] Group 4: Company Overview - Quantum BioPharma is dedicated to developing innovative solutions for neurodegenerative and metabolic disorders, with a focus on its lead compound, Lucid-MS [5] - The company retains a 25.71% ownership stake in Celly Nutrition, which is involved in the development of unbuzzd™, a product related to its portfolio [5]

Core Viewpoint - Quantum BioPharma Ltd. has purchased an additional USD $1,000,000 worth of Bitcoin and other cryptocurrencies, increasing its total cryptocurrency investment to USD $2,000,000 as part of its strategic efforts to enhance shareholder returns and hedge against currency fluctuations [1][2]. Group 1: Cryptocurrency Investment Strategy - The company believes in the potential of Bitcoin and other cryptocurrencies to provide returns on investment and serve as a hedge against the Canadian dollar [2]. - Quantum BioPharma is set up to receive financing and conduct transactions in cryptocurrencies, indicating a strategic shift towards digital assets [2][3]. - All cryptocurrency holdings are managed by a fully compliant custodian, ensuring adherence to financial and audit regulations [3]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with a lead compound, Lucid-MS, aimed at preventing myelin degradation [4]. - The company retains a 25.71% ownership stake in Celly Nutrition, which is involved in the development of the unbuzzd™ product, and will receive royalty payments based on sales [4]. - Quantum BioPharma maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by real estate [4].

Core Viewpoint - Quantum BioPharma Ltd. has engaged MZHCI, LLC to enhance its investor relations and financial communications strategy, focusing on increasing visibility in the investment community and promoting its innovative product pipeline targeting brain disorders and alcohol health [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company dedicated to developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [11]. - The company is advancing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [11]. Strategic Engagement - MZ will collaborate with Quantum BioPharma's management to create a comprehensive capital markets strategy to boost the company's visibility [2]. - The engagement with MZ is for an initial period of two months at a cost of $10,000 per month, with the option for automatic renewal [8]. Product Focus - Quantum BioPharma is developing products like unbuzzd™ and rekvry™, which utilize innovative technology to address excessive alcohol use, a significant public health issue [3]. - The company is also targeting demyelinating diseases, with multiple sclerosis affecting nearly 1 million people in the U.S. and 2.8 million globally [4]. Revenue Potential - The company sees substantial revenue potential in its focus areas, particularly in addressing unmet needs in brain disorders and alcohol health [5]. - Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition, which markets unbuzzd™, and is entitled to a 7% royalty on sales until reaching $250 million, after which the royalty will decrease to 3% [11].

Core Viewpoint - Quantum BioPharma Ltd. has engaged Enterprise Canada Inc. and Empire Market Ventures, LLC to enhance its public relations and investor awareness efforts across key markets [1][2][6] Group 1: Engagement of Agencies - The decision to retain the services of Enterprise and Empire was made after a thorough review of available capital [2] - Enterprise has been engaged for an indefinite period starting December 18, 2024, with a structured payment plan totaling C$10,000 for Phase 1 and a monthly retainer of C$5,000 thereafter [3][4] - Empire has been contracted for three months starting February 7, 2025, with a total fee of US$25,000 [5][6] Group 2: Services Provided - Enterprise will assist with public relations strategy, including narrative development, key messaging, and media relationships [4] - Empire will provide investor awareness services, including access to exclusive mailing lists and content creation aimed at increasing investor engagement [6] Group 3: Product Updates - Quantum BioPharma's product unbuzzd™ is a rapid alcohol detoxification beverage, with a ready-to-drink formulation expected to be available in Q1 2025 [7][9] - rekvry™ is designed for alcohol misuse treatment, targeting emergency and hospital settings to reduce healthcare costs [7][9] - LUCID-21-302 is a new chemical entity aimed at treating demyelinating diseases, with an initial focus on multiple sclerosis [8][9] Group 4: Company Overview - Quantum BioPharma is focused on developing innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse [10] - The company retains a 25.71% ownership stake in Celly Nutrition, which markets unbuzzd™, and is entitled to a 7% royalty on sales until reaching $250 million [11]

Core Viewpoint - Quantum BioPharma Ltd. announced that its licensee, Celly Nutrition Corporation, is raising up to $10 million USD and exploring an initial public offering on a major US exchange, which indicates strong market interest in their product unbuzzd, a beverage designed to enhance alcohol metabolism and reduce hangover symptoms [1][3][4]. Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, including alcohol misuse [5]. - The company retains a 25.71% ownership stake in Celly Nutrition as of June 30, 2024, and has a royalty agreement that includes 7% of sales from unbuzzd until total payments reach $250 million, after which the royalty rate drops to 3% indefinitely [2][5]. Product Details - unbuzzd is a scientifically-backed beverage that accelerates alcohol metabolism, restores mental clarity, and alleviates hangover symptoms, appealing to consumers who wish to enjoy alcohol responsibly [7][8]. - Clinical trials demonstrated that unbuzzd reduces blood alcohol concentration (BAC) by over 40% faster than a placebo within 30 minutes, improves alertness, stabilizes heart rate and blood pressure, and significantly reduces hangover symptoms [14]. Strategic Developments - Celly Nutrition has engaged a leading New York investment bank to assist with financial advisory services and to manage a proposed public offering, indicating a strategic move towards expanding its market presence [3][6]. - The CEO of Celly Nutrition emphasized the importance of this capital raise for accelerating marketing and sales development of unbuzzd, reflecting the company's growth strategy [3].

TORONTO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has completed a double-blind, randomized, placebo-controlled crossover design clinical trial (NCT06505239) of its dietary supplement product unbuzzd™, investigating its effects on alcohol intoxication and alcohol metabolis ...